Blood Donors on Medication: An Approach to Minimize Drug Burden for Recipients of Blood Products and to Limit Deferral of Donors

The study addressed the eligibility of blood donors on medication by categorizing drugs into four classes based on their pharmacological properties and assessing blood products by their single-donor plasma content. It concluded that donors on medication could donate blood products containing less than 50 ml of single-donor plasma, such as red blood cell concentrates, for adult use without deferral periods, except for those taking specific teratogenic or genotoxic drugs, which require waiting periods. Drugs with dose-dependent pharmacodynamics did not necessitate deferral for certain blood products, while irreversible inhibitors of platelet function required a 10-day waiting period for platelet concentrate production.